1. American Diabetes Association Professional Practice Committee. Improving care and promoting health in populations: standards of care in diabetes 2024. Diabetes Care. 2024;47:S11–S19. doi: 10.2337/dc24-S001
2. Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options.Circulation.2021;143:1157–1172.doi:10.1161/CIRCULATIONAHA.120.050686
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation.2003;108:2154–2169.
4. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P,Nowack C, Schloemer P, Joseph A, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N Engl J Med. 2020;383:2219–2229. doi: 10.1056/NEJMoa2025845
5. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A,Kolkhof P, Nowack C, Schloemer P, et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–2263. doi: 10.1056/NEJMoa2110956
6. Bauersachs J, López-Andrés N. Mineralocorticoid receptor in cardiovascular diseases: clinical trials and mechanistic insights. Br J Pharmacol.3134;2022:3119. doi: 10.1111/bph.15708
7. Georgianos PI, Agarwal R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int Rep. 2021;6:2281–2291. doi:10.1016/j.ekir.2021.05.027
8. Belden Z, Deiuliis JA, Dobre M, Rajagopalan S. The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature. Am J Nephrol. 2017;46:298–314. doi: 10.1159/000480652
9. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M. Effect of eplerenone, a selective aldosterone blocker, on blood pressure,serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003;41:955–963. doi:10.1097/00005344-200306000-00019
10. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212–2216. doi: 10.1161/01.cir.0000015854.60710.10
11. Rajagopalan S, Dobre M, Dazard JE, Vergara-Martel A, Connelly K, Farkouh ME, Gaztanaga J, Conger H, Dever A, Razavi-Nematollahi L, Fares A, Pereira G, Edwards-Glenn J, Cameron M, Cameron C, Al-Kindi S, Brook RD, Pitt B, Weir M. Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial. Circulation. 2024 Aug 12.. Epub ahead of print. PMID: 39129649.
12. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, et al; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal- PLAQUE):a randomised clinical trial. Lancet. 2011;378:1547–1559. doi:10.1016/S0140-6736(11)61383-4
13. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM,Davignon J, Erbel R, Fruchart JC, Tardif J-C, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565. doi:10.1001/jama.295.13.jpc60002
14. McDiarmid AK, Swoboda PP, Erhayiem B, Bounford KA, Bijsterveld P, Tyndall K, Fent GJ, Garg P, Dobson LE, Musa TA, et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. J Am Heart Assoc. 2020;9:e011521. doi:10.1161/JAHA.118.011521
15. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 1838;108:1831–1838. doi:10.1161/01.cir.0000091405.00772.6e
16. Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation.2021;143:516–525. doi: 10.1161/CIRCULATIONAHA.120.052186
17. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial.Circulation.2019;140:1693–1702.doi:10.1161/CIRCULATIONAHA.119.042375
18. Connelly KA, Sarak B. Diabetes and myocardial fibrosis: is CMR the force leading to the rise of “scar wars?” JACC Cardiovasc Imaging. 2022;15:809–811. doi: 10.1016/j.jcmg.2022.01.015
19. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122:624–638. doi:10.1161/circresaha.117.311586
20. McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Eur Heart J.1725;35:1719–1725. doi: 10.1093/eurheartj/eht565
21. Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Sarafidis P, Schmieder RE, Joseph A, Rethemeier N, et al; FIDELIO-DKD Investigators. Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension. 2022;79:2685–2695. doi:10.1161/HYPERTENSIONAHA.122.19744
22. Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ,Brunner-La- Rocca HP, Clark AL, Cosmi F, Cuthbert J, et al. Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Heart Fail. 2021;9:268–277. doi: 10.1016/j.jchf.2020.11.010
23. Cai D, Clayton LK, Smolyar A, Lerner A. AND-34, a novel p130Cas-binding thymic stromal cell protein regulated by adhesion and inflammatory cytokines. J Immunol. 1999;163:2104–2112.